Spiral Therapeutics closes USD 27m Series B to advance inner ear disorder treatments

Spiral Therapeutics, a clinical-stage biotechnology company based in South San Francisco focused on inner ear disorders, [closed](https://www.prnewswire.com/news-releases/spiral-therapeutics-announces-27-million-series-b-financing-and-strategic-partnership-with-advanced-bionics-302741713.html) a USD 27 million Series B financing alongside a strategic R&D collaboration with cochlear implant manufacturer Advanced Bionics. Gund Investment led the round, with new strategic participation from Advanced Bionics and an undisclosed global pharmaceutical company. Ferring Ventures, Uni-Bio Science Group, and other existing investors also participated. The company said proceeds will support development of its lead candidate SPT-2101 and expansion of its proprietary MICS (Minimally Invasive Cochlear System) drug delivery platform. The Series B follows an USD 8.25 million financing completed in January 2023, which initiated a Phase II trial in Ménière's disease, and a USD 5.6 million Series A closed in 2019. The concurrent R&D collaboration with Advanced Bionics is designed to explore sustained local drug delivery at the time of cochlear implantation, with the goal of improving outcomes for cochlear implant recipients by combining device and therapeutic approaches. SPT-2101, a sustained-release dexamethasone formulation [for Ménière's disease](https://www.spiraltx.com/spiral-therapeutics-announces-successful-completion-of-the-spt-2101-phase-1b-2a-clinical-trial-for-menieres-disease-data-presented-during-the-2024-aao-annual-meeting/), is the company's lead programme. The drug delivered a statistically significant reduction in overall vertigo in a prior study, and Spiral said it is now preparing for a registrational clinical trial. The candidate was acquired as part of an asset purchase from Otonomy, where it had been developed as OTO-104. Beyond SPT-2101, the pipeline includes neurotrophic programmes targeting sensorineural hearing loss, which the company said are designed to address the neurodegeneration of spiral ganglion neurons underpinning auditory decline. The MICS platform is engineered to deliver therapeutics directly to the round window membrane — the anatomical interface between the middle ear and the cochlear fluid — bypassing the blood-labyrinth barrier that limits systemic drug access to inner ear tissues. The platform is designed to achieve sustained drug concentrations in the perilymph over clinically relevant durations, a pharmacokinetic challenge that has constrained drug development in otology. Spiral has drawn parallels to the ophthalmology field, where sustained local delivery to another barrier-protected sensory compartment has established a precedent for the approach. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/spiral-therapeutics-series-b-funding-closes-usd)